3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thrombosis
1
Sarcoma, Alveolar Soft Part
1
Pulmonary Embolism
1
Prostatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma
1
Interventions
Dexamethasone
277
Lenalidomide
155
Bortezomib
152
Cyclophosphamide
115
Melphalan
107
Calcium Dobesilate
107
fludarabine phosphate
70
carfilzomib
61
pomalidomide
55
Peripheral Blood Stem Cell Transplantation
53
Whole-Body Irradiation
52
Mycophenolic Acid
52
Granulocyte Colony-Stimulating Factor
52
Filgrastim
52
daratumumab
46
fludarabine
43
Tacrolimus
41
ixazomib
40
Busulfan
40
Thalidomide
36
Cyclosporine
32
dexamethasone acetate
26
Stem Cell Transplantation
26
Antilymphocyte Serum
25
dexamethasone 21-phosphate
22
plerixafor
20
auricularum
20
belantamab mafodotin
19
Prednisone
19
Etoposide
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Multiple Myeloma
×
Warfarin
×
Clear all
NCT00790842
2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2
Terminated
63 enrolled
14 charts